Waters (WAT) Q2 2026 Earnings Call Transcript
Waters (WAT) reported Q2 2026 revenue of $1.645 billion, above the top of guidance, with 9% organic growth and adjusted EPS of $3.05. Full-year 2026 guidance was raised to 7% to 9% organic revenue growth and adjusted EPS of $14.45 to $14.65. Management cited cost actions, FX headwinds, China DRG headwinds, and progress in acquired biosciences and diagnostics.
How this was made
The 30-second read
Why it matters
The most tradable items are the raised full-year organic revenue growth and adjusted EPS range, plus Q3 guidance, supported by pricing realization and an accelerated instrument replacement cycle. Offsetting risks include stronger USD impacts on EPS and ongoing China DRG headwinds.
Market read
Guidance raise plus segment and product catalysts (FDA 510(k) clearance, upcoming FACSDiscover A7 launch) likely drive revisions to near-term earnings expectations, while FX and China remain key risk factors.
What to watch
The call emphasizes lumpy chemical analysis ordering and reagent rental compliance remediation, which could create quarter-to-quarter variability despite overall growth.
Background
This is a transcript of Waters’ Q2 2026 earnings call, covering segment performance, integration progress, cost savings, and updated guidance.
Ticker impact
Waters reported Q2 2026 revenue of $1.645B, raised full-year organic growth to 7% to 9%, and guided Q3 EPS to $3.95 to $4.05.
Bias toward near-term upside as guidance is raised, with volatility risk from USD strength and China DRG-driven softness.
The transcript includes explicit guidance raises (full-year and Q3) plus quantified drivers (cost actions, FX translation, China drag), which are directly tradable inputs for earnings models and positioning.
Market effects
Signals strength in analytical instruments and diagnostics demand, including GLP-1 testing growth and instrument replacement cycle tailwinds.
Highlights China as a continuing drag tied to DRG headwinds, while Analytical Sciences in China is growing double digits.
Supports broader life-science tools sentiment via reshoring capex tracking and FDA clearance for a new blood culture system.
Counterpoint
FX translation and China DRG headwinds could offset operational gains, making the guidance raise more fragile than it appears.
Key entities
- companyWaters Corporation
Reported Q2 2026 results, raised full-year guidance, and provided Q3 EPS and revenue growth outlook.
- executiveUdit Batra
CEO cited portfolio launch timing and discussed China DRG headwinds and product performance claims.
- executiveAmol Chaubal
CFO quantified EPS drivers including cost actions and USD translation effects.
- partnerIMU Biosciences
Announced strategic partnership to scale a precision immunology platform for AI-enabled precision medicine.
